Mineralys Therapeutics, Inc.
MLYS
$14.25
$0.755.56%
| Weiss Ratings | MLYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | MLYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | MLYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.09 | |||
| Price History | MLYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 42.36% | |||
| 30-Day Total Return | 38.75% | |||
| 60-Day Total Return | 19.75% | |||
| 90-Day Total Return | 6.50% | |||
| Year to Date Total Return | 16.33% | |||
| 1-Year Total Return | 13.10% | |||
| 2-Year Total Return | -15.83% | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -26.19% | |||
| 52-Week Low % Change | 63.82% | |||
| Price | MLYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $18.29 | |||
| 52-Week Low Price | $8.24 | |||
| 52-Week Low Price (Date) | Feb 25, 2025 | |||
| 52-Week High Price (Date) | Mar 10, 2025 | |||
| Valuation | MLYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 672.78M | |||
| Enterprise Value | 474.59M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.64 | |||
| Earnings Per Share Growth | 82.83% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 3.52 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $14.25 | |||
| Enterprise Value/EBITDA (TTM) | -2.47 | |||
| Enterprise Value/EBIT | -2.47 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | MLYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 49.96M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | MLYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 888 378 6240 | |||
| Address | 150 N. Radnor Chester Rd. Radnor, PA 19087 | |||
| Website | mineralystx.com | |||
| Country | United States | |||
| Year Founded | 2019 | |||
| Profitability | MLYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | MLYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -52.56% | |||
| Return on Equity | -- | |||
| Income Statement | MLYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -192.36M | |||
| EBIT (TTM) | -192.40M | |||
| Net Income (TTM) | -177.81M | |||
| Net Income Avl. to Common (TTM) | -177.81M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -100.69% | |||
| EPS Diluted (TTM) | -3.64 | |||
| EPS Diluted Growth (Q YOY) | -61.02% | |||
| Balance Sheet | MLYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 198.19M | |||
| Cash Per Share (Q) | $3.97 | |||
| Total Current Assets (Q) | 205.35M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 191.26M | |||
| Current Ratio (Q) | 14.021 | |||
| Book Value Per Share (Q) | $3.84 | |||
| Total Assets (Q) | 205.90M | |||
| Total Current Liabilities (Q) | 14.65M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 14.65M | |||
| Total Common Equity (Q) | 191.26M | |||
| Cash Flow | MLYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 114.96M | |||
| Cash from Financing (TTM) | 116.14M | |||
| Net Change in Cash (TTM) | 64.79M | |||
| Levered Free Cash Flow (TTM) | -99.43M | |||
| Cash from Operations (TTM) | -166.31M | |||
